白蛋白纳米容器与甲氨蝶呤和硫酸软骨素作为双重pH/ gsh应答肿瘤靶向纳米药物协同治疗癌症。

IF 9.6 Q1 ENGINEERING, BIOMEDICAL
Biomaterials research Pub Date : 2025-09-03 eCollection Date: 2025-01-01 DOI:10.34133/bmr.0245
Haroon Iqbal, Anam Razzaq, Ziyin Yuan, Lina Zhai, Yue Wang, Uzair Ur-Rehman, Lv Man, Jun Xin, Xin Ning, Yuanbo Liang, Run Xiao
{"title":"白蛋白纳米容器与甲氨蝶呤和硫酸软骨素作为双重pH/ gsh应答肿瘤靶向纳米药物协同治疗癌症。","authors":"Haroon Iqbal, Anam Razzaq, Ziyin Yuan, Lina Zhai, Yue Wang, Uzair Ur-Rehman, Lv Man, Jun Xin, Xin Ning, Yuanbo Liang, Run Xiao","doi":"10.34133/bmr.0245","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer is a devastating disease, and its pathogenesis is highly associated with malnutrition and poor lifestyle. Chemotherapy continuously causes inadequate therapeutic efficacy and induces off-target toxicities. Hence, targeted co-administration of chemotherapy and dietary supplement producing anticancer effect at low doses with minimized toxicities would be a promising strategy for cancer treatment. In this study, we constructed chondroitin sulfate (CS) and methotrexate (MTX) carried serum albumin nanocages (C/M@Alb NCs) by albumin nanoreactor strategy. During fabrication, we achieved the precipitation of MTX and CS inside the albumin nanocore under mild reaction condition to prepare C/M@Alb NCs. The enhanced anticancer efficacy of C/M@Alb NCs was comprehensively assessed by in vitro and in vivo experiments. Biodistribution, pharmacokinetic profile, and in vivo therapeutic efficacy of C/M@Alb NCs were investigated in human colorectal adenocarcinoma (HT-29), murine breast cancer (E0071), and patient-derived (PDX) lung cancer models. The as-prepared C/M@Alb NCs facilitated higher MTX and CS encapsulation, exhibiting small particle size, improved colloidal stability, dual stimuli (pH/GSH)-responsive drug release profile, an enhanced cellular uptake, cooperative synergistic cytotoxicity, extended blood residence time, improved lymph node and tumor targeting, and in vivo therapeutic efficacy against various cancers such as human colorectal adenocarcinoma, murine breast cancer, and patient-derived (PDX) lung cancer. Altogether, C/M@Alb NCs exhibited enhanced cellular uptake, extended blood residence time, and favorable tumor accumulation and lymph node extravasation, finally leading to the potent antitumor efficacy against various cancers. This nanoplatform offers a new strategy for designing lymph node- and cancer-targeted albumin-based nanomedicine for clinical applications.</p>","PeriodicalId":93902,"journal":{"name":"Biomaterials research","volume":"29 ","pages":"0245"},"PeriodicalIF":9.6000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407586/pdf/","citationCount":"0","resultStr":"{\"title\":\"Albumin Nanocages with Methotrexate and Chondroitin Sulfate as a Dual pH/GSH-Responsive Tumor Targeting Nanomedicine for Synergistic Cancer Therapy.\",\"authors\":\"Haroon Iqbal, Anam Razzaq, Ziyin Yuan, Lina Zhai, Yue Wang, Uzair Ur-Rehman, Lv Man, Jun Xin, Xin Ning, Yuanbo Liang, Run Xiao\",\"doi\":\"10.34133/bmr.0245\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cancer is a devastating disease, and its pathogenesis is highly associated with malnutrition and poor lifestyle. Chemotherapy continuously causes inadequate therapeutic efficacy and induces off-target toxicities. Hence, targeted co-administration of chemotherapy and dietary supplement producing anticancer effect at low doses with minimized toxicities would be a promising strategy for cancer treatment. In this study, we constructed chondroitin sulfate (CS) and methotrexate (MTX) carried serum albumin nanocages (C/M@Alb NCs) by albumin nanoreactor strategy. During fabrication, we achieved the precipitation of MTX and CS inside the albumin nanocore under mild reaction condition to prepare C/M@Alb NCs. The enhanced anticancer efficacy of C/M@Alb NCs was comprehensively assessed by in vitro and in vivo experiments. Biodistribution, pharmacokinetic profile, and in vivo therapeutic efficacy of C/M@Alb NCs were investigated in human colorectal adenocarcinoma (HT-29), murine breast cancer (E0071), and patient-derived (PDX) lung cancer models. The as-prepared C/M@Alb NCs facilitated higher MTX and CS encapsulation, exhibiting small particle size, improved colloidal stability, dual stimuli (pH/GSH)-responsive drug release profile, an enhanced cellular uptake, cooperative synergistic cytotoxicity, extended blood residence time, improved lymph node and tumor targeting, and in vivo therapeutic efficacy against various cancers such as human colorectal adenocarcinoma, murine breast cancer, and patient-derived (PDX) lung cancer. Altogether, C/M@Alb NCs exhibited enhanced cellular uptake, extended blood residence time, and favorable tumor accumulation and lymph node extravasation, finally leading to the potent antitumor efficacy against various cancers. This nanoplatform offers a new strategy for designing lymph node- and cancer-targeted albumin-based nanomedicine for clinical applications.</p>\",\"PeriodicalId\":93902,\"journal\":{\"name\":\"Biomaterials research\",\"volume\":\"29 \",\"pages\":\"0245\"},\"PeriodicalIF\":9.6000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407586/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomaterials research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34133/bmr.0245\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomaterials research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34133/bmr.0245","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

摘要

癌症是一种毁灭性的疾病,其发病机制与营养不良和不良生活方式密切相关。化疗不断导致治疗效果不足,并诱发脱靶毒性。因此,有针对性地联合化疗和膳食补充剂,以低剂量和最小的毒性产生抗癌效果,将是一种很有前途的癌症治疗策略。本研究采用白蛋白纳米反应器策略构建了硫酸软骨素(CS)和甲氨蝶呤(MTX)携带血清白蛋白纳米笼(C/M@Alb NCs)。在制备过程中,我们在温和的反应条件下实现了MTX和CS在白蛋白纳米核内的沉淀,制备了C/M@Alb纳米核。通过体外和体内实验综合评价C/M@Alb NCs的增强抗癌作用。研究了C/M@Alb NCs在人结直肠癌(HT-29)、小鼠乳腺癌(E0071)和患者源性肺癌(PDX)模型中的生物分布、药代动力学特征和体内治疗效果。制备的C/M@Alb nc具有更高的MTX和CS包封性,具有粒径小、胶体稳定性好、双重刺激(pH/GSH)反应性药物释放谱、增强细胞摄取、协同增效细胞毒性、延长血液停留时间、改善淋巴结和肿瘤靶向性,以及对各种癌症(如人类结直肠癌、小鼠乳腺癌和患者源性肺癌)的体内治疗效果。总之,C/M@Alb NCs表现出增强的细胞摄取,延长的血液停留时间,有利的肿瘤积聚和淋巴结外渗,最终导致对各种癌症的有效抗肿瘤功效。该纳米平台为临床应用设计淋巴结和癌症靶向白蛋白纳米药物提供了一种新的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Albumin Nanocages with Methotrexate and Chondroitin Sulfate as a Dual pH/GSH-Responsive Tumor Targeting Nanomedicine for Synergistic Cancer Therapy.

Cancer is a devastating disease, and its pathogenesis is highly associated with malnutrition and poor lifestyle. Chemotherapy continuously causes inadequate therapeutic efficacy and induces off-target toxicities. Hence, targeted co-administration of chemotherapy and dietary supplement producing anticancer effect at low doses with minimized toxicities would be a promising strategy for cancer treatment. In this study, we constructed chondroitin sulfate (CS) and methotrexate (MTX) carried serum albumin nanocages (C/M@Alb NCs) by albumin nanoreactor strategy. During fabrication, we achieved the precipitation of MTX and CS inside the albumin nanocore under mild reaction condition to prepare C/M@Alb NCs. The enhanced anticancer efficacy of C/M@Alb NCs was comprehensively assessed by in vitro and in vivo experiments. Biodistribution, pharmacokinetic profile, and in vivo therapeutic efficacy of C/M@Alb NCs were investigated in human colorectal adenocarcinoma (HT-29), murine breast cancer (E0071), and patient-derived (PDX) lung cancer models. The as-prepared C/M@Alb NCs facilitated higher MTX and CS encapsulation, exhibiting small particle size, improved colloidal stability, dual stimuli (pH/GSH)-responsive drug release profile, an enhanced cellular uptake, cooperative synergistic cytotoxicity, extended blood residence time, improved lymph node and tumor targeting, and in vivo therapeutic efficacy against various cancers such as human colorectal adenocarcinoma, murine breast cancer, and patient-derived (PDX) lung cancer. Altogether, C/M@Alb NCs exhibited enhanced cellular uptake, extended blood residence time, and favorable tumor accumulation and lymph node extravasation, finally leading to the potent antitumor efficacy against various cancers. This nanoplatform offers a new strategy for designing lymph node- and cancer-targeted albumin-based nanomedicine for clinical applications.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信